Background: For quality analysis, we applied the Six Sigma concept to define quality indicators and their boundaries as well as to compare treatment-dependent outcome data of deep brain stimulation (DBS) of the subthalamic nucleus (STN) in patients with Parkinson's disease (PD). Methods: The Unified Parkinson Disease Rating Scale (UPDRS) III with on medication and on stimulation, the reduction of daily levodopa equivalence doses (LED), and the stimulation amplitude 1 year after surgery were registered. Regarding the results of the EARLYSTIM study, sigma values for applicable studies were calculated and compared. Further, the impact of perioperative conditions on patients' outcomes was analyzed. Results: Forty-one studies with 2184 patients were included. The bleeding risk was 1.36%. In median, UPDRS III on/on improved by 19.9% while the LED was reduced by 45.2%. The median stimulation amplitude was 2.84 V. With the Six Sigma principle, a comparison between different centers was possible. Microelectrode recordings (MER) did not correlate with occurrence of bleedings and did not impact patient outcome. Conclusions: The Six Sigma principle can be simply used to analyze, improve and compare complex medical processes, particularly, the DBS surgery. Based on these data, higher sigma values were reached for clinical improvement in UPDRS III on/on for patients who underwent surgery in local anesthesia with intraoperative test stimulation compared to surgery in general anesthesia. However, the difference was not statistically significant. Application of MER was found to be optional with no increased bleeding risk and no improvement on patient's outcome.
Introduction
Six Sigma, developed by Motorola in the 1980s [1] , is a widespread quality management concept to achieve a practicable zero defect quality in complex processes. Besides improvement cycles, i.e. DMAICDefine, Measure, Analyze, Improve, Control, it includes an objective measurement concept to calculate the actual quality level of each process step. Based on standard normal distribution assumption, the sigma value is the key performance indicator of the Six Sigma concept. A Six Sigma process performance equals a quality level of 99.99966% or a max of 3.4 'defects per million opportunities' (DPMO). Thereby, a defect is defined as deviation of a self-determined standard. In some economic areas, like in production of aircraft turbines or medical technology (particularly, in life support devices) such as a 'zero defect target' as a self-selected standard is mandatory. In the medical field, such standards are linked to patient requests, so-called 'critical to quality characteristics' (CTQs), patient safety or the minimum requirements for patient outcome [2] . The Six Sigma concept was already applied successfully in the neurosurgical perioperative organization process with an improved patient safety and medical staff satisfaction [3] , in the emergency room [4] , in surgical site infections [5] and in turnaround time in the operation room [6] . Recent studies revealed an increased use of Six Sigma in various medical fields [7] . Deep brain stimulation (DBS) of the subthalamic nucleus (STN-DBS) in patients with Parkinson's Disease (PD) is a widespread and accepted therapy when medically intractable fluctuations and dyskinesia [8] occur and it has proven to have stable long-term efficacy [9] . The success of this procedure is markedly dependent on the accuracy of the lead placement. Although the gold standard of DBS surgery is the operation on awake patients with intraoperative neurological examination and microelectrode recordings (MER), the procedure is done in various manners within numerous centers. There is an ongoing dispute about, whether the surgery should be performed under local anesthesia with MER [10] or general anesthesia with preand postoperative MRI control [11] to reduce patients' intraoperative stress. Further, the targeting methods used in DBS depend on the familiarity of the surgeon in charge. There are centers which use MRI as the only targeting tool [12] , while others merge a stereotactic CT with the MRI for optimal targeting [13] or even perform a ventriculography [14] . Each neurosurgeon in charge assesses different crucial perioperative processing steps, whereas the actual impact on the outcome of the patients is unknown. There are neither criteria that define a 'successful' DBS surgery nor there are factors that allow a simple and clear comparison between different surgical centers. Furthermore, in neurosurgery, possible errors may lead to irreparable harm of patients with far-reaching consequences for lifetime and quality. Therefore, a pro-active strategy is needed to avoid such errors.
The aim of this study was to evaluate whether the Six Sigma principle is feasible to determine evidence-based quality indicators, to compare these quality factors between different operation centers with different operating strategies and to monitor the impact of perioperative changes for the patients' outcome.
Methods

DMAIC-cycle
In the Define phase, we generated a SIPOC (Supplier, Input, Process, Output and Costumer) table for DBS surgery. After brainstorming within a team of all participants, we determined CTQ factors that might have an influence on the objective. These three possible indicators for patient improvement and process optimization were determined regarding clinical experience and the results of the EARLYSTIM study [15] . Although the patient population of the EARLYSTIM study differs from prior studies, this study was used to define therapeutic borders, since it marks a new algorithm with less affected PD patients who undergo a DBS surgery in the future.
For the Measure and Analyze phase, it was essential that the CTQ factors were clearly defined and easy to gather. Thereby, the results of the EARLYSTIM study and the 2.8% significance level of each indicator, were used as acceptable boundaries. If an indicator was outside of this threshold, the surgery was defined as a failure (Figure 1) .
In daily living, relevant clinical improvements for patients can be measured by the Unified Parkinson Disease Rating Scale (UPDRS) III with on medication and on stimulation. This value may be gathered without additional effort and should be reduced at least~15% due to the surgery. This was calculated out of the median improvement of 26% with an SD of 5.6% [15] . Further, the daily medication, standardized to the calculated levodopa equivalence doses (LED) [16] , which may lead to less pharmacological side effects and an improvement of patients' quality of life, should be diminished at least~35% (median reduction of 39% with a SD of 2%) [15] . Since both values may influence each other (e.g. less improvement in UPDRS III may be compensated with a pronounced LED reduction), an aggregated sigma value was calculated to rate the therapeutic success of the surgery.
Additionally, to minimize the frequency of stimulator changes or charges, the stimulation amplitude should not exceed 4.2 V (median amplitude of 2.8 V with an SD of 0.7 V) [15] . Although the battery life is also dependent on the frequency, the impulse length and the active electrode contacts, the stimulation amplitude as the only value was chosen consciously, since the data acquisition and the calculation should be suitable for daily living. Additionally, the stimulation amplitude may serve as an indirect marker for lead deviation, since higher deviations require higher stimulations amplitudes for clinical improvements. All values were assessed preoperatively and at least 8 months after surgery. Finally, intra-and postoperative symptomatic bleedings should not occur at all. Although other complications are imaginable, especially bleedings may lead to irreparable brain damage with consecutive permanent disability and deteriorated quality of life.
Literature review
In all available studies of DBS surgery into the STN of the last 15 years with information about median UPDRS III on/on, LED reduction and stimulation amplitude and their standard deviations at least Figure 1 Distribution chart of LED to determine the threshold of 2.8% significance level.
8 months after surgery were reviewed and the sigma values of each study were calculated. Studies with incomplete information were excluded. Further, perioperative settings including MRI/CT fusion, postoperative MRI control, intraoperative use of MER and test stimulation with surgery in local anesthesia were assessed and their impact on patients' outcome was calculated.
Calculations
The median (x) for expected value μ and the standard deviation (s) for variance σ of every indication value were calculated and used for error rate determination: • NORM.S.INV (1 − d) + 1.5 to compute the long-term Sigma Value σ of each indicator of each study by realigning the defect rate with standard normal distribution. Thereby, 1 − d represents the quality rate or yield. Since processes usually underlie natural fluctuations in long-term performance, an empiricallybased 1.5 shift was included in the calculation based on international standard [17] . Since in medical fields DPMO is not practicable, the therapeutic yield was calculated via the normal distribution of the sigma value.
• POWER(RTY;1/3) to calculate the normalized Rolled-Throughput Yield (RTY) of each study. For RTY calculation, independent yields (1 − d i ) of the three indicators are multiplied.
Statistics
The values are expressed as mean ± standard deviation. The significance level was calculated with a Mann-Whitney U-test and Chi-square test using SPSS software.
Results
Forty-one studies with a total of 2184 patients were applicable for calculation of the sigma values. To facilitate the comparison between the different studies, the included patient number of the study, the main patient characteristics, the median outcome data of the patients and the perioperative settings were mentioned. The Tables 1 and 2 ). There was no significant difference of the bleeding risk between surgery with or without MER (1.65% vs. 1.19%; P = 0.6).
The intraoperative stimulation and testing was foregone in five reports. In 19 studies, a fusion of a stereotactic CT and a MRI was performed. In 32 reports intraoperative MER for target verification were applied. In 23 reports the lead placement was controlled with an MRI, while in 12 studies the placement was either controlled by CT, ventriculography, stereotactic X-ray or even not at all (see Table 3 ).
The median sigma value for the improvement of UPDRS III on/ on of at least 15% was 1.56, which means a therapeutic yield of 52.6%, while for the median LED reduction of at least 35% a sigma value of 2.09 and a yield of 72.2% was calculated. The median sigma value of the stimulation amplitude was 3.98 and the yield was 99.34%. The median therapeutic sigma value was 2.72 with a therapeutic yield of 88.9%. This means, that for 88.9% of the patients, the defined borders for 'successful' reduction of LED or improvement in UPDRS III on/on were reached. The highest sigma value for UPDRS III on/on improvement was calculated for Schuepbach et al. [15] with 3.14 (median 26% improvement), while the values for [8] Not specified Not specified Not specified Not specified Zibetti et al. [52] Yes Yes Yes Yes LED reduction and stimulation amplitude were 3.1 (median 39% reduction) and 3.5 (median 2.8 V). Moro et al. [9] reached the highest sigma value for LED reduction with 5.93 (median 55.4% reduction) with values for UPDRS III on/on improvement of 1.58 (median 18.8% improvement) and stimulation amplitude of 3.7 (median 3.1 V). Therefore, the therapeutic sigma value of this study was also the highest, measured at 6.11. For further details regarding all included studies, see Table 4 . The impact of the perioperative settings on the different sigma values was analyzed. The improvement of UPDRS III on/on reached a higher sigma value when patients underwent the surgery in local anesthesia without any significance level. MER and preoperative fusion of CT and MRT showed no influence on patients' outcome or on stimulation amplitude. The only significant correlation was calculated between a reduction of the LED and intraoperative stimulation with better results for patients, who were operated in general anesthesia (for further details see Table 5 ).
Discussion
DBS within the STN for treatment of PD is a complex procedure which is performed in various manners. A direct comparison between different operation centers is still difficult. Therefore, we applied the Six Sigma principle to compare patients' outcome in Table 4 Sigma values of included studies. Doubled studies represent each arm within the study. *1 According to calculation, the theoretical sigma value was −1.58. The observation time for *2 was 4 years, for *3 2 years and for *4 3 years postoperatively. LED (levodopa equivalence dose); UPDRS (Unified Parkinson Disease Rating Scale) different STN-DBS studies, which is the first time this has been done in the literature. Since the used boundaries of the CTQ factors were not haphazardly selected but were based on the results of the EARLYSTIM study [15] , it is now meaningful to compare different DBS centers directly, which may lead to an active and purposeful conferencing within the various performed DBS surgery. To illustrate this, sigma values for all available studies of the past 15 years with about 1-year follow-up of patients who underwent a DBS surgery into the STN were analyzed and the sigma values were calculated. Since the sigma value depends not only on the level of the improvement, but also on the scatter range of the values, it may obviously differ although the median clinical outcome is similar. For example, the sigma value for similar improvement of the UPDRS III in Fraix et al. 2006 [26] (improvement of 35.8%) is only 1.9, while Vesper et al. [49] (improvement of 33.3%) revealed a sigma value of 2.77. Thus, the sigma value is not only a representation of the median clinical improvement, but also of the continuous quality of the surgery for the entirety of the treated patients. Although the three determined quality factors cannot consider this complex procedure in all its particulars, they may still comment on the patients' outcome and surgical quality and are simple to gather without any additional effort. Therefore, this quality tool may be transferred simply into clinical daily living for self-control. The UPDRS IV as an additional CTQ factor would be favorable, but only a few publications assessed this score completely pre-and postoperatively. Thus, no analysis of this factor was possible. Our analysis for the impact of the perioperative settings on the different sigma values in the current literature showed no correlation between the application of MER and the occurrence of bleedings, with a bleeding risk of 1.42% for STN-DBS in contrast to recent reports [53] . This might be explainable by the fact that only STN-DBS reports were included in our analysis with an additional selection bias (see study selection criterias in the Method section of this paper) and only STN-DBS patients where regarded. Further, the application of MER, the fusion of stereotactic CT and MRI and the postoperative control with an MRI showed no impact on patients' outcome or stimulation amplitude. The sigma value of UPDRS III on/on improvement of patients, which were operated under local anesthesia, was higher compared to general anesthesia, but no significance was reached. This confirms recent findings that intraoperative test stimulation with MER might be overestimated and effects of permanent stimulation and side effects are not predictable [54] .
The only significant correlation was found between intraoperative stimulation and the reduction of LED, with higher sigma values of patients who were operated under general anesthesia. This seems to be a bias, since there was a significant difference in LED before surgery between patients which underwent the surgery under general anesthesia (LED: 1406 mg) and local anesthesia (LED 1192 mg). Therefore, the reduction could be more pronounced (58% in general anesthesia vs. 45% in local anesthesia). These results should be handled with care since there might be a selection bias due to the inclusion criteria of the evaluated studies (see above). Prospective, randomized and multicenter studies are needed to elucidate this dispute.
Since PD patients are a very heterogeneous group and in DBS surgery numerous critical steps exists, the calculated sigma values are in general below industrial standard of 3.8σ.
However, in contrast to economical procedures with the aim of reaching Six Sigma quality with less possible error sources and homogenous products, in medical processes, where patient outcome and surgical success are considered, the aim should be the monitored improvement of both factors. For better comparability between different DBS centers with different operation procedures, we encourage all authors to provide further information in future studies of these essential CTQ factors like UPDRS III on/on and IV improvement, LED reduction, stimulation amplitude, occurrence of bleedings and operation time. Further applications of Six Sigma in other medical fields have to be proven to elucidate hidden possible improvements in patient care and comparability of different surgical centers.
The Six Sigma concept can be simply used to analyze, improve, control and compare complex medical processes, particularly, DBS surgery. It is an easy-to-apply method to monitor the impact of perioperative changes for the patients' outcome. In contrast to a simple Meta-Analysis, the implementation of the Six Sigma concept allows not only for a statistic and quantitative reappraisal, but also the definition of borders for successful therapy outcomes. Thus, for the first time, determination of evidence-based therapeutic success rates in terms of quality of earnings is possible. Exemplarily for DBS surgery, higher sigma values were reached for clinical improvement in UPDRS III on/on for patients who underwent the surgery under local anesthesia with intraoperative test stimulation compared to surgery in general anesthesia without any significance, while the application of MER is optional with no increased bleeding risk and no improvement on patient outcome. Based on these data, STN-DBS patients may be operated under general anesthesia with comparable clinical results.
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